Justin Linhorst, MBA

Ideally, these contracts help address criticism of the 340B program, improve patient outcomes, and increase compliance.

The cancer care system lags in comparison to other chronic health conditions in this key area.

Timely access to cancer treatment improves patient outcomes.

As health care costs rise and cost-sharing increases, treatment-associated expenses will continue to burden patients.

Dealing with a cancer diagnosis is difficult, but patients with MM have reason to be hopeful. Survival rates are on the rise, and a robust pipeline of promising immunotherapies and novel treatment options are in development.

The past decade has seen a rapid expansion in technology adoption.